Coherus Announces U.S. Launch Of LOQTORZI; Offers First And Only FDA-Approved Treatment For NPC In All Lines Of Therapy
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences, Inc. (NASDAQ: CHRS) has launched LOQTORZI, the first and only FDA-approved treatment for nasopharyngeal carcinoma (NPC) in all lines of therapy. LOQTORZI is now available through select specialty distributors and is indicated for use in combination with chemotherapy for first-line treatment and as monotherapy for patients with disease progression after platinum-containing chemotherapy. The launch follows positive results from the JUPITER-02 and POLARIS-02 studies, which showed significant improvements in progression-free survival and overall survival. Coherus aims to make LOQTORZI the new standard of care for NPC and is committed to supporting patients with programs to reduce out-of-pocket costs.
January 02, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences has launched LOQTORZI, the first FDA-approved NPC treatment, which could become the new standard of care. This launch may significantly boost the company's revenues and market position.
The launch of LOQTORZI by Coherus is a significant event as it is the only FDA-approved treatment for NPC, addressing an unmet medical need. The positive clinical trial results and the potential establishment as a new standard of care suggest a positive outlook for the company's product sales and revenue growth. The company's commitment to patient support programs may also enhance market penetration and brand loyalty. Given these factors, the short-term impact on CHRS stock is likely to be positive, assuming market conditions and broader sector performance do not negatively influence the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100